Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21047607 | 1.00 | OPRM1 (0.42) | OPRM1OPRL1MAPK1OPRK1TP53BP1 | |
| SCHEMBL21049492 | 1.00 | OPRM1 (0.42) | OPRM1OPRL1MAPK1OPRK1TP53BP1 | |
| SCHEMBL21047650 | 1.00 | OPRM1 (0.42) | OPRM1OPRL1MAPK1OPRK1TP53BP1 | |
| SCHEMBL21047702 | 1.00 | OPRM1 (0.42) | OPRM1OPRL1MAPK1OPRK1TP53BP1 | |
| SCHEMBL21047910 | 0.98 | OPRM1 (0.40) | OPRM1OPRL1MAPK1OPRK1TP53BP1 | |
| SCHEMBL21047677 | 0.96 | MAPK1 (0.40) | OPRM1OPRL1MAPK1TP53BP1L3MBTL3 | |
| SCHEMBL2927719 | 0.94 | OPRM1 (0.41) | OPRM1OPRL1MAPK1TP53BP1L3MBTL3 | |
| SCHEMBL21047822 | 0.91 | L3MBTL3 (0.37) | OPRM1OPRL1MAPK1TP53BP1L3MBTL3 | |
| SCHEMBL21047786 | 0.89 | OPRM1 (0.43) | OPRM1OPRL1MAPK1OPRK1TP53BP1 | |
| SCHEMBL21047698 | 0.89 | OPRM1 (0.43) | OPRM1OPRL1MAPK1OPRK1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
| CN-109563016-A | Using single hydrogen perfluoro alkane as the manufacturing method of the all-fluoroalkyl compound of starting material | 关东电化工业株式会社 | 2019-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | OPRM1 1846/4885OPRL1 3095/4885MAPK1 709/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | OPRM1 1846/4885OPRL1 3095/4885MAPK1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.